Role of VLDL receptor in atherogenesis.


Journal

Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000

Informations de publication

Date de publication:
01 08 2021
Historique:
entrez: 6 7 2021
pubmed: 7 7 2021
medline: 24 2 2022
Statut: ppublish

Résumé

My group previously discovered and characterized the rabbit and human VLDL receptors. For more than 30 years, I have focused on research regarding the functions of VLDL receptors in the fields of lipoprotein metabolism and atherogenesis. In this review, I introduce the roles of VLDL receptors in lipoprotein metabolism under physiological conditions and in atherogenesis under nonphysiological conditions. I propose that the VLDL receptor plays key roles in the metabolism of postprandial remnant lipoproteins in concert with lipoprotein lipase (LPL). Furthermore, I propound a new mechanism for macrophage foam cell formation via VLDL receptors by remnant lipoproteins and lipoprotein(a) [Lp(a)] in addition to scavenger receptor pathways. The VLDL receptor is a so-called macrophage β-VLDL receptor, which is involved in macrophage foam cell formation by remnant lipoproteins. Furthermore, Lp(a) is a VLDL receptor ligand and is directly taken up through macrophage VLDL receptors for macrophage foam cell formation. Additionally, the roles of VLDL receptors in atherogenesis are canvassed. http://links.lww.com/COL/A21.

Identifiants

pubmed: 34227576
doi: 10.1097/MOL.0000000000000760
pii: 00041433-202108000-00003
doi:

Substances chimiques

Lipoprotein(a) 0
Lipoproteins, VLDL 0
Receptors, LDL 0
VLDL receptor 0

Types de publication

Journal Article Review Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-225

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39:27–38.
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34–47.
Takahashi S, Kawarabayasi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 1992; 89:9252–9256.
Sakai J, Hoshino A, Takahashi S, et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269:2173–2182.
Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271:6852–6860.
Takahashi S. Triglyceride rich lipoprotein -LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell formation. J Atheroscler Thromb 2017; 24:552–559.
Takahashi S, Suzuki J, Kohno M, et al. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 1995; 270:15747–15754.
Niemeier A, Gafvels M, Heeren J, et al. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res 1996; 37:1733–1742.
Yagyu H, Lutz EP, Kako Y, et al. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem 2002; 277:10037–10043.
Goudriaan JR, Espirito Santo SM, Voshol PJ, et al. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 2004; 45:1475–1481.
Argraves KM, Battey FD, MacCalman CD, et al. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem 1995; 270:26550–26557.
Imagawa M, Takahashi S, Zenimaru Y, et al. Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression. Clin Chim Acta 2012; 413:441–447.
Takahashi S, Oida K, Ookubo M, et al. Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3. FEBS Lett 1996; 386:197–200.
van Dijk KW, van Vlijmen BJ, van der Zee A, et al. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler Thromb Vasc Biol 1998; 18:7–12.
Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 2005; 46:1721–1731.
Multhaupt HA, Gafvels ME, Kariko K, et al. Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. Am J Pathol 1996; 148:1985–1997.
Wyne KL, Pathak K, Seabra MC, Hobbs HH. Expression of the VLDL receptor in endothelial cells. Arterioscler Thromb Vasc Biol 1996; 16:407–415.
Kamataki A, Takahashi S, Masamura K, et al. Remnant lipoprotein particles are taken up into myocardium through VLDL receptor--a possible mechanism for cardiac fatty acid metabolism. Biochem Biophys Res Commun 2002; 293:1007–1013.
Takahashi S, Sakai J, Fujino T, et al. The very low density lipoprotein (VLDL) receptor--a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol Cell Biochem 2003; 248:121–127.
Takahashi S, Sakai J, Fujino T, et al. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb 2004; 11:200–208.
Nakajima K, Tokita Y, Tanaka A, Takahashi S. The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins. Clin Chim Acta 2019; 495:382–393.
Takazawa T, Yamauchi T, Tsuchida A, et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem 2009; 284:30049–30057.
Iwasaki T, Takahashi S, Takahashi M, et al. Deficiency of the very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor. Endocrinology 2005; 146:3286–3294.
Zenimaru Y, Takahashi S, Takahashi M, et al. Glucose deprivation accelerates VLDL receptor-mediated TG-rich lipoprotein uptake by AMPK activation in skeletal muscle cells. Biochem Biophys Res Commun 2008; 368:716–722.
Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med 2016; 20:17–28.
Orekhov AN. LDL and foam cell formation as the basis of atherogenesis. Curr Opin Lipidol 2018; 29:279–284.
Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019; 40:537–557.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017; 69:692–711.
Nakazato K, Ishibashi T, Shindo J, et al. Expression of very low density lipoprotein receptor mRNA in rabbit atherosclerotic lesions. Am J Pathol 1996; 149:1831–1838.
Hiltunen TP, Luoma JS, Nikkari T, Yla-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998; 97:1079–1086.
Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100:2170–2181.
Kosaka S, Takahashi S, Masamura K, et al. Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages. Circulation 2001; 103:1142–1147.
Tacken PJ, Delsing DJ, Gijbels MJ, et al. VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area. Atherosclerosis 2002; 162:103–110.
Eck MV, Oost J, Goudriaan JR, et al. Role of the macrophage very-low-density lipoprotein receptor in atherosclerotic lesion development. Atherosclerosis 2005; 183:230–237.
Takahashi S, Ito T, Zenimaru Y, et al. Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expression. Biochem Biophys Res Commun 2011; 407:656–662.
Suzuki J, Takahashi S, Oida K, et al. Lipid accumulation and foam cell formation in Chinese hamster ovary cells overexpressing very low density lipoprotein receptor. Biochem Biophys Res Commun 1995; 206:835–842.

Auteurs

Sadao Takahashi (S)

Division of Diabetes, Ageo Central General Hospital, Saitama.
Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH